Takashi Kojima

15PUBLICATIONS
73CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 05, 2026
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).

|Mar 06, 2026
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.

Hisanaga Nomura, Takaya Suzuki, Takashi Kojima

|Dec 19, 2025
Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients.

Shinpei Ushiyama, Takumi Habu, Izuma Nakayama

|Aug 01, 2025
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.

Amane Jubashi, Izuma Nakayama, Naoya Sakamoto

|Feb 19, 2025
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).

Hideaki Bando, Shogo Kumagai, Daisuke Kotani

|Dec 12, 2024
Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration.

Shunsuke A Sakai, Koichi Saeki, SungGi Chi

Pageof 3

Frequent Collaborators

7 joint publications

Hideaki Bando

6 joint publications

Kohei Shitara

5 joint publications

Ken Kato

4 joint publications

Takayuki Yoshino